Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product (BGY-1601-VT) as a First-line Monotherapy in Women With Acute Vaginal Infection: a Randomized, Double-blind, Placebo-controlled Study

NCT06450990 is registered in ClinicalTrials.gov with NEXBIOME THERAPEUTICS as lead sponsor.

NCT NCT06450990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06450990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product (BGY-1601-VT) as a First-line Monotherapy in Women With Acute Vaginal Infection: a Randomized, Double-blind, Placebo-controlled Study
Lead sponsor
NEXBIOME THERAPEUTICS
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 8, 2024
Completion date
February 26, 2026
Enrollment
165 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial vaginosis, vulvovaginal candidiasis